glp 1 agonist moa glp-1_analogs [TUSOM Mechanisms of GLP-1 Receptor Agonist-Induced

Retatrutide has higher rates of nausea, diarrhea, and vomiting than tirzepatide

Amycretin is a next-generation unimolecular dual GLP-1/amylin receptor agonist that showed up to 24.3% weight loss in early trials, substantially exceeding semaglutide and potentially exceeding even CagriSema

Antacids: Famotidine or Omeprazole can help with acid reflux or heartburn (OTC or prescription depending on dose)

New oral GLP-1 drugs could offer more options for weight loss GLP-1 injections require refrigeration and needles

In studies with rats and mice, Saxenda and medicines that work like Saxenda caused thyroid tumors, including thyroid cancer

A: Current trial data suggests orforglipron may produce around 9% to 10% body weight reduction in some populations, while injectable semaglutide has shown higher average weight-loss outcomes in longer trials